

| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,864.80 | 1,787.05 | 2,028.44 | 1,947.61 | 1,725.42 |
| Total Expenses | 1,741 | 1,691.55 | 1,923.08 | 1,729.05 | 1,518.99 |
| Profit Before Tax | 123.80 | 95.50 | 105.36 | 218.56 | 206.43 |
| Profit After Tax | 90.80 | 69.60 | 78.38 | 160.50 | 133.14 |
| Operating Profit After Depreciation | 199 | 151.87 | 153.47 | 249.78 | 242.62 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,364.50 | 1,070.63 | 958.39 | 889.07 | 721.40 |
| Total Non Current Assets | 1,533.50 | 1,520.53 | 1,446.46 | 1,248.83 | 1,034.62 |
| Total Current Assets | 995.40 | 966.62 | 939.02 | 964.28 | 878.60 |
| Total Assets | 2,528.90 | 2,487.15 | 2,385.48 | 2,213.11 | 1,913.22 |
| Total Shareholder's Fund | 1,262.30 | 1,187.66 | 1,133.47 | 1,067.98 | 933.40 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 280.40 | 186.70 | 315.31 | 293.73 | 229.02 |
| Net Cash Used In Investing Activities | -136.50 | -173.70 | -292.34 | -284.37 | -156.20 |
| Net Cash Used In Financing Activities | -143.60 | -27 | -7.68 | -5.56 | -96.87 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,864.80 | 1,787.05 | 2,028.44 | 1,947.61 | 1,725.42 |
| Total Expenses | 1,740.90 | 1,691.63 | 1,923.08 | 1,729.04 | 1,518.99 |
| Profit Before Tax | 123.90 | 95.41 | 105.36 | 218.57 | 206.43 |
| Profit After Tax | 90.90 | 69.51 | 78.38 | 160.51 | 133.14 |
| Operating Profit After Depreciation | 199.10 | 151.78 | 153.46 | 249.79 | 242.62 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,364.50 | 1,070.63 | 958.39 | 889.07 | 721.40 |
| Total Non Current Assets | 1,532.20 | 1,520.54 | 1,446.47 | 1,248.84 | 1,034.63 |
| Total Current Assets | 996.90 | 966.53 | 939 | 964.28 | 878.60 |
| Total Assets | 2,529.10 | 2,487.07 | 2,385.48 | 2,213.12 | 1,913.23 |
| Total Shareholder's Fund | 1,262.20 | 1,187.59 | 1,133.49 | 1,068.01 | 933.42 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 280.40 | 186.60 | 315.29 | 293.73 | 229.02 |
| Net Cash Used In Investing Activities | -136.50 | -173.70 | -292.34 | -284.37 | -156.20 |
| Net Cash Used In Financing Activities | -143.60 | -27 | -7.68 | -5.56 | -96.87 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 318.50 | 380.40 | 552.40 | 447.70 | 452.90 |
| Total Expenses | 311.30 | 355.30 | 429 | 375.60 | 378 |
| Profit Before Tax | -47 | -30.40 | 68.30 | 23.80 | 24.80 |
| Profit After Tax | -34.90 | -22.40 | 50.20 | 17.20 | 18.30 |
| Operating Profit after Depreciation | 9.10 | 26.10 | 123.90 | 75.70 | 75.30 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 318.50 | 380.40 | 552.40 | 447.70 | 452.90 |
| Total Expenses | 311.10 | 355.60 | 428.90 | 375.50 | 378.20 |
| Profit Before Tax | -46.80 | -30.70 | 68.40 | 23.90 | 24.60 |
| Profit After Tax | -34.70 | -22.70 | 50.30 | 17.30 | 18.10 |
| Operating Profit after Depreciation | 9.30 | 25.80 | 124 | 75.80 | 75.10 |
₹0.8/Share
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,763.70 | ₹4,23,170.71 |
| Divis Laboratories Ltd | ₹6,523.25 | ₹1,73,171.79 |
| Torrent Pharmaceuticals Ltd | ₹3,816.75 | ₹1,29,170.36 |
| Cipla Ltd | ₹1,536.25 | ₹1,24,093.85 |
| Dr Reddys Laboratories Ltd | ₹1,244.50 | ₹1,03,868.61 |
On 6 November 2025
01 Nov 2025, 10:26 am
Hikal slipped 1.80% to Rs 248.85 after the company announced that it has received a warning letter from the US Food and Drug Administration (US FDA) for its Jigani facility in Bengaluru, Karnataka.
22 Aug 2025, 10:23 am
On 23 September 2025
08 Aug 2025, 01:48 pm
On 7 August 2025
01 Aug 2025, 11:06 am
Hikal said that it has successfully cleared the Good Manufacturing Practices (GMP) inspection conducted by the Brazilian Health Regulatory Agency (ANVISA) at its API manufacturing unit in Jigani, Bengaluru, Karnataka.
17 Jun 2025, 11:35 am

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Congratulations,
Your Digital savings bank account opening journey is complete.